Outcomes in Human Immunodeficiency Virus Infected Recipients of Heart and Lung Transplants by Chen, Chao et al.
University of Rhode Island
DigitalCommons@URI
Pharmacy Practice Faculty Publications Pharmacy Practice
2018
Outcomes in Human Immunodeficiency Virus
Infected Recipients of Heart and Lung Transplants
Chao Chen
Xuerong Wen
University of Rhode Island, xuerongwen@uri.edu
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs
The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy
Articles, as set forth in our Terms of Use.
This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in
Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Chen C, Wen X, Yadav A, Belviso N, Kogut S, McCauley J. Outcomes in human immunodeficiency virus‐infected recipients of heart
transplants. Clin Transplant. 2018;e13440. https://doi.org/10.1111/ctr.13440 Available at: https://doi.org/10.1111/ctr.13440
Authors
Chao Chen, Xuerong Wen, Nicholas Belviso, Stephen Jon Kogut, and Jerry McCauley
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/133
CONFIDENTIAL
 
 
 
 
 
 
Outcomes in Human Immunodeficiency Virus Infected 
Recipients of Heart and Lung Transplants  
 
 
Journal: American Journal of Transplantation 
Manuscript ID Draft 
Wiley - Manuscript type: O - Original Article 
Date Submitted by the Author: n/a 
Complete List of Authors: Chen, Chao; University of Florida, Pharmaceutical Outcomes and Policy 
Wen, Xuerong; University of Rhode Island, Health Outcomes 
Belviso, Nicholas ; University of Rhode Island, Health Outcomes 
Kogut, Stephen ; University of Rhode Island, Health Outcomes 
McCauley, Jerry; Thomas Jefferson University 
Keywords - Scope: health services and outcomes research, clinical research / practice 
Keywords - Discipline: 
heart transplantation / cardiology, infectious disease, lung transplantation / 
pulmonology 
Keywords - Focus: 
infection and infectious agents, viral: human immunodeficiency virus (HIV) 
/ acquired immunodeficiency syndrome (AIDS), patient survival, graft 
survival 
  
 
 
amjtransplant@duke.edu
American Journal of Transplantation
CONFIDENTIAL
Outcomes in Human Immunodeficiency Virus Infected Recipients of 
Heart and Lung Transplants  
Chen Chao1, BS, Xuerong Wen2, PhD, Nicholas Belviso2, PharmD, Stephen Kogut2*, 
PhD, Jerry McCauley3*, MD 
1: Department of Pharmaceutical Outcomes and Policy, University of Florida, 
Gainesville, Florida 
2: Health Outcomes, University of Rhode Island, Kingston, RI 
3: Department of Nephrology, Thomas Jefferson Medical School, Philadelphia, PA 
*: These authors contributed equally.  
 
 
Abbreviations 
HIV, Human Immunodeficiency Virus 
cART, combined antiretroviral therapy 
SRTR, Scientific Registry of Transplant Recipients 
BMI, body mass index 
HLA, human leukocyte antigen 
PRA, panel reactive antibody 
HBc, hepatitis B core 
HCV, hepatitis C virus 
EBV, Epstein-Barr virus  
CMV, cytomegalovirus 
ATG, anti-thymocyte globulin 
IL-2, interleukin-2 
DCM, dilated cardiomyopathy 
CAD, coronary artery disease 
DRS, disease risk score  
HTR, heart transplant recipient 
LTR, lung transplant recipients 
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IPF, idiopathic pulmonary fibrosis 
COPD, chronic obstructive pulmonary disease  
SD, standard deviation 
IQR, interquartile range 
XMATCH, histocompatibility cross match 
CI, confidence interval 
ISHLT, International Society for Heart Lung Transplantation 
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Abstract 
Background 
With the advent of combined antiretroviral therapy (cART), growing evidence has shown 
Human Immunodeficiency Virus (HIV) may no longer be an absolute contraindication for 
solid organ transplantation. This study compared outcomes of heart and lung 
transplantations between HIV positive and HIV negative recipients from a large 
transplant registry.  
Methods 
Patient survival, overall graft survival and death-censored graft survival were compared 
between HIV positive and HIV negative recipients. Multivariate Cox regression and Cox 
regression with a disease risk score (DRS) methodology were used to estimate the 
adjusted hazard ratios among heart transplant recipients (HTRs). Descriptive analysis 
was performed for HIV-positive lung transplant recipients (LTRs). 
Results 
In total 35 HTRs and 6 LTRs with HIV were identified. No significant difference was 
found in patient survival (88% vs 77%; p=0.1493), overall graft survival (85% vs 76%; 
p=0.2758) and death-censored graft survival (91% vs 91%; p=0.9871) between HIV 
positive and HIV negative HTRs in 5-year follow-up. No significant differences were 
found after adjusting for confounders. Among 6 HIV positive LTRs, two patients died in 
their first and fourth year after transplantation respectively. 
Conclusions 
This study supports the use of heart and lung transplant procedures in selected HIV 
positive patients.  
(Words count: 197)  
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Introduction 
Traditionally, transplantation eligibility hinged on a strict set of patient specific 
criteria. Patients infected with Human Immunodeficiency Virus (HIV) were generally 
excluded (1-3). The scarcity of donor organs forced practitioners to only consider 
patients with the best prognosis because success is dependent on a lifetime of 
adherence to a complex medication regimen (4). Furthermore, with continual 
immunosuppressant therapy as the mainstay in post-operative treatment, patients with 
immunocompromising conditions, such as HIV, may be more prone to adverse health 
outcomes (2, 5). Studies in early 1990s consistently showed shorter incubation periods 
for advanced disease and lower survival rates in transplant recipients infected with HIV 
(5-8). Additionally, some immunosuppressive therapies may inhibit the development of 
CD4+ T cells in patients after transplantation (9-11). However, with the introduction of 
combined antiretroviral therapy (cART) in 1996, survival and quality of life have 
improved markedly in HIV infected patients (12-14). The estimated 10-year survival rate 
in patients treated with cART exceeds 90%; denoting a shift in classifying HIV as an 
chronic infective process  rather than an acute illness (15). In this new treatment era, 
studies supporting renal and hepatic transplantations in HIV infected patients have 
shown promising results (16-19). In contrast, limited instances of heart and lung 
transplants restricts the evidence to observational case studies (20, 21).  
Even though transplantation may be the last chance of survival for patients with 
end-stage disease (22), many transplant centers remain reluctant to perform these 
procedures on patients infected with HIV (23). Despite recent reports suggesting that 
patients with HIV do not experience poorer health outcomes when compared to 
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uninfected transplant recipients (24-26), many clinicians remain steadfast in the 
antiquated eligibility guidelines. The case series study by Uriel et al. reported a 100% 
survival rate over a 5-year period without development of AIDS-defining illnesses 
among 7 HIV positive patients who received heart transplants (26). Similarly, Kern et al. 
reviewed three case studies of lung transplantations among patients with HIV infection 
and suggested that it might be a promising option for patients with selected end-stage 
lung disease (27) However, in the defense of the reluctant clinicians, these case reports 
are not comprehensive enough to provide conclusive evidence for supporting heart and 
lung transplantations in HIV infected patients. Therefore, this study aims to provide 
some guidance by evaluating heart and lung transplant outcomes among HIV positive 
and HIV negative recipients using a large transplant registry in the United States.  
 
Methods 
Data Source 
This study used data from the Scientific Registry of Transplant Recipients 
(SRTR). The SRTR data system includes data on all donor, wait-listed candidates, and 
transplant recipients in the US, submitted by the members of the Organ Procurement 
and Transplantation Network (OPTN), and has been described elsewhere (28). The 
Health Resources and Services Administration (HRSA), U.S. Department of Health and 
Human Services provides oversight to the activities of the OPTN and SRTR contractors. 
This study utilized longitudinal clinical and demographic data on each patient from 
2004-2016. It has been approved by the University of Rhode Island Institutional Review 
Board (IRB#955723-3). 
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Study Design 
Outcomes in HIV positive transplant recipients were compared to HIV negative 
recipients in this retrospective cohort study.  All patients who received a heart and/or 
lung transplant over the age of 18 were included. Any patients who received other organ 
transplants or who did not have a conclusive HIV serology at the time of transplantation 
were excluded from the study.  
Patients were followed from the date of transplantation until the first occurrence 
of any of the following: end of the fifth transplant year, re-transplantation, death, graft 
failure, and loss of SRTR follow-up. The endpoints were defined as ‘patient survival’, 
‘overall graft survival’, and ‘death-censored graft survival’. Death with functioning graft 
was censored in ‘death-censored graft survival’ analysis, but treated as an event in 
‘overall graft survival’. 
 
Statistical Analysis 
Baseline cohort characteristics were summarized by calculated group means and 
standard deviations for continuous variables and proportional frequencies and 
percentages for categorical variables. Student t-tests and chi-square tests were used to 
quantify statistically significant differences in baseline characteristics between the HIV 
positive and negative groups. The Fischer’s exact test was adopted, instead of Chi-
square test, where any cell had an observed count less than five. The Kaplan–Meier 
analysis and log-rank test were used to compare the crude risk of transplantation 
outcomes between HIV positive and HIV negative recipients. 
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Multivariate Cox regression was used to adjust for confounders between HIV 
positive and HIV negative groups. Covariates investigated in this study included patient 
age, gender, race, recipient educational level, calendar year of transplantation, body 
mass index (BMI), receipt of induction therapy, baseline viral serology, primary 
cardiovascular diseases, number of human leukocyte antigen (HLA) recipient to donor 
mismatch, pre-transplant panel reactive antibody (PRA), histocompatibility cross match 
results, steroids regimen use, and ventricular assist device use. Besides HIV status, 
other pre-transplant viral antibody serology status were also examined, including 
hepatitis B core (HBc), hepatitis C virus (HCV), Epstein-Barr virus (EBV) and 
cytomegalovirus (CMV). The induction therapy utilized was classified as anti-thymocyte 
globulin (ATG), alemtuzumab, interleukin-2 (IL-2) inhibitors including basiliximab or 
daclizumab, other induction therapy and no induction. Primary diagnoses, defined as 
the reasons for receiving transplantation, were adjusted for and included dilated 
cardiomyopathy (DCM), coronary artery disease (CAD) and other diseases. 
Transplantation in HIV infected recipients is relatively infrequent and could 
impact the validity of traditional multivariate regression with exposure propensity score 
(29-31). Disease risk score (DRS) is better suited for studies with rare exposures and 
was adopted as an alternative for the adjustment of confounders (30, 32). This method 
has been validated by previous simulated and observational studies (29, 33). To 
calculate DRS, each study outcome was regressed over the entire cohort on both the 
exposure variable and covariates (32).The score was compiled from the fitted values of 
the model for each study subject when setting the individual exposure variable to 
unexposed (32). The quintiles of the DRS were used for covariate adjustment within the 
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final Cox regression model to derive adjusted hazard ratios between HIV positive and 
negative patients with better precision (34).  
All analyses were performed using SAS software, version 9.4 (SAS Institute Inc, 
Cary, NC). Statistical significance was based on a P value less than 0.05 and all 
confidence intervals used a 95% threshold. 
 
Results 
Thirty-five HIV-positive adult heart transplant recipients (HTRs) and 6 HIV-
positive lung transplant recipients (LTRs) were identified using SRTR data from 2004 
through 2016. The demographic and clinical characteristics of these 41 HIV-positive 
cases were summarized in table 1 and table 2 respectively. Statistical analyses 
between HIV negative and HIV positive LTRs were not conducted due to the limited 
number of observed occurrences. The 35 HTRs with positive HIV consisted of 25 male 
(71.43%) and 10 female (28.57%) patients with an average age of 49 years (SD: 12.00). 
In comparison, HTRs with a negative HIV serology were mostly male (74.66%) with a 
mean age of 53 years (SD: 12.80). Almost half of the transplantations among HIV-
positive patients (51.14%) occurred in 2014-2016, while only about one-fourth of HIV-
negative patients (25.95%) received transplantation in this period. HIV-positive HTRs 
had a significantly higher rate of chronic viral infections including hepatitis B (31.43% vs 
4.51%, p<0.001), hepatitis C (8.56% vs 1.93%, p=0.0491), and cytomegalovirus 
(85.71% vs 59.35%, p=0.0341). Additionally, HIV-positive HTRs were less likely to have 
received anti-thymocyte globulin (ATG) as induction therapy; although, this comparison 
is not statistically significant (8.57% vs 19.49%, p=0.3438). HIV-positive HTRs had a 
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higher frequency of coronary arterial disease as a primary medical diagnosis when 
compared to patients without HIV infection (11.43% vs 4.18%, p = 0.0289). There were 
significantly more HIV-positive HTRs with a college level education (68.57% vs 48.93%, 
p=0.0461).  
The median follow-up times were 2.00 years for HIV-positive HTRs and 3.00 
years for HIV-negative HTRs. Among the 35 HIV-positive HTRs, two patients died at 
2.78 and 2.93 years respectively and one patient did not receive a successful 
transplant. The remaining patients survived the whole study period with a functioning 
graft. Even though the results were inconclusive, HIV-positive HTRs appeared to have a 
better patient survival (1-year: 100% vs 89%, 3-year: 88% vs 83%, 5-year: 88% vs 77%; 
p=0.1493), overall graft survival (1-year: 97% vs 89%, 3-year: 85% vs 82%, 5-year: 85% 
vs 76%; p=0.2758), and death-censored graft survival rates (1-year: 97% vs 96%, 3-
year: 91% vs 93%, 5-year: 91% vs 91%; p=0.9871) (Figure 1 a, b, and c). Adjusting for 
demographic and clinical characteristics using a multivariate Cox regression or DRS 
adjustment model did not alter the results (Figure 2).  
Among the 6 HIV-positive LTRs, all patients were white with ages varying 
between 50 to 70 years old. Three patients had a BMI>30, one patient was female, and 
only one did not have a college-level education. Two patients were infected with 
Hepatitis B, all six patients were coinfected with cytomegalovirus and Epstein Barr virus, 
and none of the patients were infected with Hepatitis C. Four patients received 
transplants due to idiopathic pulmonary fibrosis (IPF) and one due to chronic obstructive 
pulmonary disease (COPD). Two patients were lost to follow-up immediately after 
transplantation, one patient was censored at the fourth year, and another was censored 
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at the fifth year. No graft failures were observed for these four patients. The remaining 
two patients died in 116 days and 1541 days after transplantation. 
 
Discussions 
Throughout the 12-year study period, 35 HTRs and 6 LTRs were infected with 
HIV; which, to our knowledge is the largest study conducted on heart and lung 
transplantations among HIV patients. When comparing transplantation outcomes within 
the total cohort (N=21,435), there was no significant difference in the rates of patient 
survival or graft failure. Consistent with previous reports, these findings suggest that 
both heart and lung transplantations may be viable options for selected HIV infected 
patients (20, 26, 27).  
 While Aguero et al. summerized previous studies showing the 1-, 2-, and 5-year 
survival rates for HIV-postive HTRs of 90-100%, 90-100%, and 63% (20), the survival 
rates in this study exhibited a more encouraging 5-year survival rate of 88%. Compared 
to Kern et al. study, in which all three LTRs remained alive during the study period with 
the longest follow-up time surpassing 4 years (27), our study observed two LTRs who 
died in their first and fourth year after transplantation, two who were lost to follow-up 
immediately after transplantation, and two who remained alive for more than four years 
post-transplant. HIV-positive LTRs had acceptable outcomes with wide variabillity but 
displayed a higher risk of poorer outcomes when compared to HIV-positive HTRs. The 
selection of transplant candidates should be cautious, as many factors may affect the 
transplant outcomes, for example, HCV positivity will put HIV patients at greater risk 
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than non-HIV patients after liver transplantation (16). Therefore more cases are required 
to examine the factors that impact health outcomes between these groups.  
Overall, the knowledge of heart and lung transplantat outcomes among HIV 
recipients remains limited, despite the developing evidence on the safety and efficacy of 
kidney and liver transplants (35, 36). Similar to arguments of these kidney and liver 
transplant studies, this analysis suggests that HIV positivity in heart and lung transplant 
cadidates should not signify automatic exclusion. 
HIV-infected patients are more likely to develop cardiovascular diseases 
including cardiomyopathy, coronary arterial disease, myocarditis, cardiomegaly, and 
malignancy (37-39). Similarly, HIV is assoicated with an increased risk of chronic 
obstrutive pulmonary disease, pulmonary fibrosis, pulmonary arterial hypertension, and 
lung cancer (40-42). It would be adventageous to develop a clear understanding of the 
outcomes and risks of heart tranplantations and lung transplantations in this patient 
group. Furthermore, HIV infection is no longer considered an absolute contraindication 
in the updated consensus guidelines developed by the International Society for Heart 
Lung Transplantation (ISHLT) (43, 44). However, most transplant centers still remain 
reluctant to perform heart or lung transplants within this population because of the 
concerns for infection, HIV reactivation by immunosuppressants, and drug-drug 
interactions (23). Even though the published literature on this topic is in its adolescent 
stages, this study indicates that the stigma associated with HIV on heart and lung 
transplant outcomes should be revisisted. 
While these findings provide promising results derived from the largest known 
cohort of HIV positive heart and lung transplant recipeints, the conclusions remain 
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vulnerable to several study limitations. The most prominent of which, is the lack of HIV-
positive heart and lung transplant cases observed within the registry. We suspect that 
as time progresses more cases will be captured. However, because this study can only 
make inferences about the observations included within the registry, the validity of the 
derived estimates remains inconclusive.  
Additionally, the SRTR provides limited information about the baseline, pre-
operative, and post-operative clinical depiction of each patient. For example, information 
regarding the viral load, CD4 count, or instances of AIDS opportunisitc infection are 
absent. This can introduce uncertainty when comparing outcomes across transplant 
recipients; who, may be suffering from varying levels of HIV severity. In contrast, HIV 
infected individuals who progress to the solid organ waiting-list may be healthier than 
the average HIV patient. In many reports, the HIV-infected patients selected exhibited 
undetectable viral loads, moderate CD4 counts, and a lack of AIDS-related infections. 
This limits the generalizatbillity of results to a healthier HIV subpopulation and 
introduces an unavoidable, systemic selection bias.   
Along with the lack of markers depicting the clinical health of each patient, this 
dataset is incapable of evaluating medication adherence. The complicated home-
medication regimen that the average transplant recipeint recieves can increase in 
complexity when the common drug-drug interactions between antiretroviral therapies 
and immunosuppressive therapies are introduced. If patients with superb medication 
adherence experienced better health oucomes than those with moderate or suboptimal 
adherence, this effect would never be identified.  
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While these limitations are not all-inclusive or completely avoidable, the results 
still indicate that HIV status should not trigger automatic exclusion from transplant 
elgibillity. Instead, clinicians should review HIV-positive transplant cindidates under 
updated criteria. Further research is required to develop a clearer understanding of the 
variables that impact health outcomes in HIV-positive heart and lung transplant 
recipeints as these procedures could improve prognosis by many years. 
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Table 1. Demographic and clinical characteristics of US heart transplant recipients (HIV-positive vs. 
HIV-negative) from 2004 through 2016 
Variables HIV positive  
N=35 
HIV negative 
N=21400 
p 
Year of transplant 
2004-2006 
2007-2009 
2010-2013 
2014-2016 
Pretransplant viral serology 
 
1 (2.86) 
5 (14.29) 
11 (31.43) 
18 (51.43) 
 
3772 (17.63) 
4839 (22.61) 
7236 (33.81) 
5553 (25.95) 
0.0027 
Hepatitis B antibody+ 
Hepatitis C antibody+ 
Epstein Barr virus+ 
Cytomegalovirus+ 
Induction therapy 
ATG 
Alemtuzumab  
IL-2 inhibitors 
Others 
11 (31.43) 
3 (8.57) 
27 (77.14)  
30 (85.71) 
 
3 (8.57) 
0 (0.00) 
10 (28.57) 
22 (62.86)  
965 (4.51) 
413 (1.93) 
16116 (75.31) 
12700 (59.35) 
 
4147 (19.49) 
219 (1.02) 
5918 (27.65) 
11092 (51.83) 
<0.001 
0.0491 
0.8100 
0.0341 
0.3438 
 
 
 
 
Mean age (SD)  
Age categories:  
18-45 
46-60 
Over 60 
Median follow-up years (IQR) 
Recipient race: 
White 
Black 
Hispanic 
Others 
Recipient sex 
Male 
Female 
Education level 
College 
Non-college 
Unknown 
Previous transplant 
Recipient BMI: 
0-20 
20-25 
25-30 
Above 30 
HLA mismatch >3 
Steroids use 
Ventricular assist device 
Left ventricular assist device 
48.69 (12.00) 
 
13 (37.14) 
14 (40.00) 
8 (22.86) 
2.00 (0.5, 4.98) 
 
12 (34.29) 
20 (57.14) 
2 (5.71) 
1 (2.86) 
 
25 (71.43) 
10 (28.57) 
 
24 (68.57) 
7 (20.00) 
4 (11.43) 
1 (2.86) 
 
4 (11.43) 
10 (28.57) 
13 (37.14) 
8 (22.86) 
28 (80.00) 
33 (94.29) 
15 (42.86) 
6 (17.14) 
52.64 (12.80) 
 
5246 (24.51) 
9336 (43.63) 
6818 (31.66) 
3.00 (1.00, 4.99) 
 
14549 (67.99) 
4214 (19.69) 
1717 (8.02) 
9420 (4.30) 
 
15977 (74.66) 
5423 (25.34) 
 
10470 (48.93) 
8479 (39.62) 
2451 (11.45) 
612 (2.86) 
 
1387 (6.48) 
6244 (29.18) 
7873 (36.79) 
5751 (26.87) 
16234 (75.86) 
20453 (95.57) 
6409 (29.95) 
3725 (17.41) 
0.0678 
0.1953 
 
 
 
0.1606 
<0.001 
 
 
 
 
0.6607 
 
 
0.0461 
 
 
 
1.0000 
0.7779 
 
 
 
 
0.2336 
0.6676 
0.0958 
0.9672 
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Histocompatibility cross match 
   Negative 
   Positive 
   Weak positive 
   Unknown 
Primary diagnoses: 
   DCM 
   CAD 
   Others 
 
22 (62.86) 
1 (2.86) 
1 (2.86) 
11 (31.43) 
 
30 (85.71) 
4 (11.43) 
1 (2.86) 
 
14618 (68.31) 
816 (3.81) 
202(0.94) 
5764 (26.93) 
 
17783 (83.10) 
894 (4.18) 
2723 (12.72) 
 
0.6045 
 
 
 
0.0333 
Abbreviation: HIV, Human Immunodeficiency Virus; ATG, anti-thymocyte globulin; IL-2, interleukin-2; SD, 
standard deviation; IQR, interquartile range; BMI, body mass index; HLA, human leukocyte antigen; DCM, 
dilated cardiomyopathy; CAD, coronary artery disease 
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Table2. Demographic and clinical characteristics of lung transplant HIV-positive recipients from 2004 
through 2016 
Variables Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 
Year of Transplant 
Pretransplant viral serology 
2004 2010 2012 2014 2016 2016 
   Hepatitis B antibody 
   Hepatitis C antibody 
   Epstein Barr virus 
   Cytomegalovirus 
Induction therapy 
+ 
- 
+ 
+ 
Others 
- 
- 
+ 
+ 
Others 
+ 
- 
+ 
+ 
Others 
- 
- 
+ 
+ 
IL-2 
inhibitors 
- 
- 
+ 
- 
IL-2 
inhibitors 
- 
- 
+ 
+ 
IL-2 
inhibitors 
Recipient age  
Recipient race 
Recipient sex 
Education level 
 
Recipient BMI 
HLA mismatch >3 
Steroids use 
Ventricular assist device 
Left ventricular assist 
device 
Histocompatibility cross 
match 
Primary diagnoses 
Survival days 
Death  
56 
White 
Male 
Non-
college 
Above 30 
>3 
Yes 
No 
No 
 
Negative 
 
IPF 
1826 
No 
63 
White 
Male 
College 
 
Above 30 
>3 
Yes 
No 
No 
 
Negative 
 
IPF 
1541 
Yes 
60 
White 
Male 
College 
 
   25-30 
<=3 
Yes 
No 
No 
 
Negative 
 
IPF 
1462 
No 
70 
White 
Male 
College 
 
   25-30 
>3 
Yes 
No 
No 
 
Negative 
 
IPF 
116 
Yes 
53 
White 
Female 
College 
 
   20-25 
>3 
Yes 
No 
No 
 
Unknown 
 
Others 
0 
No 
57 
White 
Male 
College 
 
Above 30 
>3 
Yes 
No 
No 
 
Unknown 
 
COPD 
0 
No 
Overall graft failure No Yes No Yes No No 
Abbreviation: HIV, Human Immunodeficiency Virus; IL-2, interleukin-2; BMI, body mass index; HLA, 
human leukocyte antigen; IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive pulmonary 
disease 
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Figure 1. Kaplan-Meier curve for patient outcomes among heart and lung transplant recipients (HIV-
positive vs. HIV-negative) 
Figure 1.a Patient Survival (P=0.1493) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.b Overall Graft Survival (P= 0.2758) 
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Figure 1.c Death-censored graft Survival (P=0.9871) 
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Figure 2 Forest plot of adjusted hazard ratios of HIV status and other significant risk factors for patient 
survival, overall graft survival and death-censored graft survival among heart transplant recipients 
Figure 2a. Forest plot of adjusted hazard ratios of HIV status and other significant risk factors for patient 
survival among heart transplant recipients  
Abbreviation: HIV, Human Immunodeficiency Virus; DRS, disease risk score; XMATCH, histocompatibility 
cross match; CI, confidence interval; ATG, anti-thymocyte globulin; IL-2, interleukin-2; BMI, body mass 
index; DCM, dilated cardiomyopathy; CAD, coronary artery disease 
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Figure 2b. Forest plot of adjusted hazard ratios of HIV status and other significant risk factors for overall 
graft survival among heart transplant recipients  
Abbreviation: HIV, Human Immunodeficiency Virus; DRS, disease risk score; XMATCH, histocompatibility 
cross match; CI, confidence interval; ATG, anti-thymocyte globulin; IL-2, interleukin-2; BMI, body mass 
index; DCM, dilated cardiomyopathy; CAD, coronary artery disease 
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Figure 2c. Forest plot of adjusted hazard ratios of HIV status and other significant risk factors for death-
censored graft survival among heart transplant recipients  
Abbreviation: HIV, Human Immunodeficiency Virus; DRS, disease risk score; XMATCH, histocompatibility 
cross match; CI, confidence interval; ATG, anti-thymocyte globulin; IL-2, interleukin-2; BMI, body mass 
index; DCM, dilated cardiomyopathy; CAD, coronary artery disease 
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